Covid vaccine Corbevax to be rolled out by Nov-end, says Biological E Ltd

On October 14, Biological E said that it would submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources.

Coronavirus vaccine, Covid-19 vaccines
ANI General News
2 min read Last Updated : Oct 26 2021 | 9:25 AM IST

To provide further momentum to the ongoing nationwide vaccination drive, the COVID-19 vaccine Corbevax vaccine will be rolled out by end of November, Biological E Limited said on Monday.

Addressing the reporters briefly after attending an event in Hyderabad, Managing Director of Biological E Limited, Mahima Datla said, "Hyderabad-based Biological E Limited is expecting its Coronavirus vaccine, Corbevax to be rolled out by the end of November. It's our vision, that on the day of the launch, we will supply close to 10 crore doses."

On October 14, Biological E said that it would submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources.

The government was expecting submission of phase 3 data of Biological E by October but after facing delay in procurement of raw materials, Hyderabad - based Biological E is expected to apply for emergency use authorisation of Corbevax by November-end.

The Corbevax is the third made-in-India vaccine against coronavirus, the other two indigenous vaccines are Covaxin and ZyCoV-D.The government earlier announced about the 30 crore doses of Corbevax by December.

The health ministry on Monday informed, "India's COVID-19 vaccination coverage has crossed 102.8 crore (1,02,86,69,053) on Monday. More than 58 lakh (58,87,981) Vaccine doses have been administered till 7 pm today. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineBiological E

First Published: Oct 26 2021 | 9:25 AM IST

Next Story